VECAM - Vecta

Drug Profile

VECAM - Vecta

Alternative Names: Esomeprazole/succinate acid; Omeprazole/succinic acid; PPI/VB101; Proton pump inhibitor/succinic acid; VB101; VB101/PPI; VCT-111; VECAM; Vecam 20/300; Vecam 40/300; VECAM-110; VECAM-111

Latest Information Update: 28 Aug 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Vecta
  • Class Antiulcers; Small molecules; Succinic acids
  • Mechanism of Action Proton pump inhibitors; Proton pump stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Gastro-oesophageal reflux

Most Recent Events

  • 28 Aug 2015 No recent reports on development identified - Phase-II for Gastro-oesophageal reflux in USA (PO)
  • 30 Jun 2011 Vecta completes a phase IIb trial in Gastro-oesophageal reflux in USA (NCT01059383)
  • 17 Sep 2010 VB 101 is available for licensing as of 30 Jun 2009. http://www.vecta.co.il
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top